Mild liver disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 40<AST<100 U/L, 40<ALT<100 U/L, or 70<r-GTP<210 U/L for male; 30<r-GTP<90 U/L for female
Exclusion criteria
Exclusion criteria: 1) Diagnosis of virus hepatitis, autoimmune hepatitis, or cirrhosis of liver 2) Taking drugs for chronic disease or continuously taking anti-flatulent, antibiotics, or purgative drug that possibly affects the intestinal flora 3) Allergy to milk 4) Participation in any clinical trial within 90 days of the commencement of the trial 5) In pregnancy or nursing a child 6) Judged as ineligible by clinical investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 16-week changes in ALT, AST, and r-GTP | — |
Secondary
| Measure | Time frame |
|---|---|
| 16-week changes in TC, HDL-C, TG, FBS, insulin, HOMA-IR, leptin, adiponectin, TNF-a, intestinal flora, and defecation frequency | — |
Countries
Japan
Contacts
Hiroshima University, Institute of Biomedical & Health Sciences Project Research Center for Clinical Trial and Preventive Medicine